Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology
- PMID: 31166401
- PMCID: PMC6544037
- DOI: 10.1590/abd1806-4841.20198607
Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology
Abstract
Hidradenitis suppurativa is a chronic immune mediated disease of universal distribution that causes great damage to the quality of life of the affected individual, whose prevalence is estimated at 0.41% in the Brazilian population. The objective of this work was update on physiopathogenesis, diagnosis and classification of hidradenitis suppurativa and to establish therapeutic recommendations in the Brazilian reality. It was organized as a work group composed of eight dermatologists from several institutions of the country with experience in the treatment of hidradenitis suppurativa and carried out review on the topic. Recommendations were elaborated and voted by modified Delphi system and statistical analysis of the results was performed. The Brazilian consensus on the clinical approach of hidradenitis suppurativa had the support of the Brazilian Society of Dermatology.
Conflict of interest statement
Conflict of interest: The members of this council declare they took part in scientific meetings, lectures and/or received support for events of the following pharmaceutical companies: Renata Ferreira Magalhães: Abbvie, Janssen-Cilag, Pfizer, Novartis and Lilly. Maria Cecília Rivitti-Machado: Abbvie and Bayer. Gleison Vieira Duarte: Abbvie, Janssen-Cilag, Leo Pharma, Galderma, Bayer, Pfizer, Novartis and Biolab. Roberto Souto: Abbvie, Novartis, Janssen-Cilag, Pfizer and Lilly. Daniel Holthausen Nunes: Abbvie, Janssen-Cilag, Novartis, Pfizer and Sanofi. Mario Chaves: Abbvie. Sérgio Henrique Hirata has no conflict of interests. Andrea Machado Coelho Ramos: Abbvie, Janssen-Cilag, Novartis and Sanofi.
Figures

References
-
- Martorell A, García-Martínez FJ, Jiménez-Gallo D, Pascual JC, Pereyra-Rodriguez J, Salgado L, et al. Actualización en hidradenitis supurativa (I): epidemiología, aspectos clínicos y definición de severidad de la enfermedad. Actas Dermosifiliogr. 2015;106:703–715. - PubMed
-
- Ianhez M, Schmitt JV, Miot HA. Prevalence of hidradenitis suppurativa in Brazil: a population survey. Int J Dermatol. 2018;57:618–620. - PubMed
-
- Gisondi P, Altomare G, Ayala F, Conti A, Dapavo P, De Simone C, et al. Consensus on the management of patients with psoriatic arthritis in a dermatology setting. J Eur Acad Dermatol Venereol. 2018;32:515–528. - PubMed
-
- Canete JD, Daudén E, Queiro R, Aguilar MD, Sánches-Carzo JL, Carrascosa, Puig L, et al. Elaboración mediante el metodo Delphi de recomendaciones para el manejo coordinado (reumatólogo/dermatólogo de la artritis psoriásica. Actas Dermassifiliogr. 2014;105:216–232.
-
- Friedman M. The use of ranks to avoid the assumption of normality implicit in the analysis of variance. Journal of the American Statistical Association. 1937;32:675–701.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources